Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 556 | Code: MRS - 7288

 

Global Markets Directs, Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2015, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD)s therapeutic pipeline.

 

This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Chronic Obstructive Pulmonary Disease (COPD) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

 

Reasons to buy

 

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

 

Table of Contents 2
 

Introduction 8
Chronic Obstructive Pulmonary Disease (COPD) Overview 9
Therapeutics Development 10
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies 12
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes 21
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance 23
Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies 27
Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes 41
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 42
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 144
Drug Profiles 161
Chronic Obstructive Pulmonary Disease (COPD) - Recent Pipeline Updates 424
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 503
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 519
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 526

Appendix 534


List of Tables
 

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2015 31
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 34
Number of Products under Development by Companies, H1 2015 (Contd..1) 35
Number of Products under Development by Companies, H1 2015 (Contd..2) 36
Number of Products under Development by Companies, H1 2015 (Contd..3) 37
Number of Products under Development by Companies, H1 2015 (Contd..4) 38
Number of Products under Development by Companies, H1 2015 (Contd..5) 39
Number of Products under Development by Companies, H1 2015 (Contd..6) 40
Number of Products under Development by Companies, H1 2015 (Contd..7) 41
Number of Products under Investigation by Universities/Institutes, H1 2015 43
Comparative Analysis by Late Stage Development, H1 2015 44
Comparative Analysis by Clinical Stage Development, H1 2015 45
Comparative Analysis by Early Stage Development, H1 2015 46
Comparative Analysis by Unknown Stage Development, H1 2015 47
Products under Development by Companies, H1 2015 48
Products under Development by Companies, H1 2015 (Contd..1) 49
Products under Development by Companies, H1 2015 (Contd..2) 50
Products under Development by Companies, H1 2015 (Contd..3) 51
Products under Development by Companies, H1 2015 (Contd..4) 52
Products under Development by Companies, H1 2015 (Contd..5) 53
Products under Development by Companies, H1 2015 (Contd..6) 54
Products under Development by Companies, H1 2015 (Contd..7) 55
Products under Development by Companies, H1 2015 (Contd..8) 56
Products under Development by Companies, H1 2015 (Contd..9) 57
Products under Development by Companies, H1 2015 (Contd..10) 58
Products under Development by Companies, H1 2015 (Contd..11) 59
Products under Development by Companies, H1 2015 (Contd..12) 60
Products under Development by Companies, H1 2015 (Contd..13) 61
Products under Investigation by Universities/Institutes, H1 2015 62
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 63
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 64
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd., H1 2015 65
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alba Therapeutics Corporation, H1 2015 66
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alchemia Limited, H1 2015 67
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2015 68
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H1 2015 69
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 70
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals, Inc., H1 2015 71
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 72
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ario Pharma Ltd, H1 2015 73
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asmacure Ltee, H1 2015 74
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc., H1 2015 75
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca PLC, H1 2015 76
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asubio Pharma Co., Ltd., H1 2015 78
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals, Inc., H1 2015 79
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Basilea Pharmaceutica AG, H1 2015 80
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs, Inc., H1 2015 81
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioheart, Inc., H1 2015 82
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotie Therapies Corp., H1 2015 83
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2015 84
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Ltd, H1 2015 85
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics, Inc., H1 2015 86
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group, Inc., H1 2015 87
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2015 88
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 89
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Corridor Pharmaceuticals Inc., H1 2015 90
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 91
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics, Inc., H1 2015 92
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 93
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Ltd., H1 2015 94
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dong Wha Pharma Co., Ltd., H1 2015 95
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics, LLC, H1 2015 96
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Five Prime Therapeutics, Inc., H1 2015 97
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 98
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2015 99
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GeneFrontier Corporation, H1 2015 100
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences, Inc., H1 2015 101
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline plc, H1 2015 103
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlycoMar Limited, H1 2015 104
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Grifols, S.A., H1 2015 105
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 106
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by High Point Pharmaceuticals, LLC, H1 2015 107
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hydra Biosciences, Inc., H1 2015 108
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica, Inc., H1 2015 109
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Limited, H1 2015 110
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 111
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H1 2015 112
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 113
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 114
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 115
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 116
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 117
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production S.p.A., H1 2015 118
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corporation, H1 2015 119
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MSM Protein Technologies, Inc., H1 2015 120
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by N30 Pharmaceuticals, H1 2015 121
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2015 122
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novabiotics Ltd, H1 2015 123
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H1 2015 124
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ockham Biotech Limited, H1 2015 125
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health, Inc., H1 2015 126
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H1 2015 127
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 128
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by P2D Bioscience, H1 2015 129
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Panmira Pharmaceuticals, LLC., H1 2015 130
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Peptinnovate Limited, H1 2015 131
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc., H1 2015 132
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by PharmaLundensis AB, H1 2015 133
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Limited, H1 2015 134
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior, Inc., H1 2015 135
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Prosonix Ltd, H1 2015 136
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmagen Therapeutics LLP, H1 2015 137
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix, Inc., H1 2015 138
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Qu Biologics Inc., H1 2015 139
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ranbaxy Laboratories Limited, H1 2015 140
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Re-Pharm Limited, H1 2015 141
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Recipharm AB, H1 2015 142
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H1 2015 143
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals SA, H1 2015 144
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rottapharm SpA, H1 2015 145
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 146
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co., Ltd., H1 2015 147
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SkyePharma PLC, H1 2015 148
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sparsha Pharma International Pvt. Ltd., H1 2015 149
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 150
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stelic Institute & Co., H1 2015 151
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stempeutics Research Private Limited, H1 2015 152
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 153
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 154
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 155
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems, Inc., H1 2015 156
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 157
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 158
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theraclone Sciences, Inc., H1 2015 159
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 160
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H1 2015 161
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corporation, H1 2015 162
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 163
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Zambon Company S.p.A., H1 2015 164
Assessment by Monotherapy Products, H1 2015 165
Assessment by Combination Products, H1 2015 166
Number of Products by Stage and Target, H1 2015 168
Number of Products by Stage and Mechanism of Action, H1 2015 174
Number of Products by Stage and Route of Administration, H1 2015 179
Number of Products by Stage and Molecule Type, H1 2015 181
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Recent Pipeline Updates, H1 2015 445
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2015 524
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..1), H1 2015 525
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..2), H1 2015 526
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..3), H1 2015 527
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..4), H1 2015 528
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..5), H1 2015 529
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..6), H1 2015 530
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..7), H1 2015 531
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..8), H1 2015 532
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..9), H1 2015 533
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..10), H1 2015 534
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..11), H1 2015 535
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..12), H1 2015 536
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..13), H1 2015 537
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..14), H1 2015 538
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..15), H1 2015 539
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2015 540
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..1), H1 2015 541
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..2), H1 2015 542
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..3), H1 2015 543
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..4), H1 2015 544
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..5), H1 2015 545
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..6), H1 2015 546


List of Figures
 

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2015 31
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 33
Number of Products under Investigation by Universities/Institutes, H1 2015 42
Comparative Analysis by Late Stage Development, H1 2015 44
Comparative Analysis by Clinical Stage Development, H1 2015 45
Comparative Analysis by Early Stage Products, H1 2015 46
Assessment by Monotherapy Products, H1 2015 165
Assessment by Combination Products, H1 2015 166
Number of Products by Top 10 Targets, H1 2015 167
Number of Products by Stage and Top 10 Targets, H1 2015 167
Number of Products by Top 10 Mechanism of Actions, H1 2015 173
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 173
Number of Products by Top 10 Routes of Administration, H1 2015 178
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 178
Number of Products by Top 10 Molecule Types, H1 2015 180
Number of Products by Stage and Top 10 Molecule Types, H1 2015 180

 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing